ABL1 is an inclusion eligibility criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain ABL1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

ABL2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ABL2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain AFF1 status and therapy-related acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].

ASXL1 is altered in 12.05% of therapy-related acute myeloid leukemia patients [2].

ASXL1 is an inclusion eligibility criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain ASXL1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

BCOR is altered in 3.61% of therapy-related acute myeloid leukemia patients [2].

BCOR is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR is an inclusion eligibility criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain BCR status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

CBL is altered in 1.2% of therapy-related acute myeloid leukemia patients [2].

CBL is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBL status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

CEBPA is altered in 7.81% of therapy-related acute myeloid leukemia patients [2].

CEBPA is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CEBPA status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

CREBBP is an inclusion eligibility criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and therapy-related acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].

CRLF2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CRLF2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain DEK status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

ELL is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ELL status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

EPOR is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains EPOR status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

ETV6 is altered in 1.2% of therapy-related acute myeloid leukemia patients [2].

ETV6 is an inclusion eligibility criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and therapy-related acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].

EZH2 is altered in 7.23% of therapy-related acute myeloid leukemia patients [2].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 3.61% of therapy-related acute myeloid leukemia patients [2].

FLT3 is an inclusion eligibility criterion in 6 clinical trials for therapy-related acute myeloid leukemia, of which 5 are open and 1 is closed. Of the trials that contain FLT3 status and therapy-related acute myeloid leukemia as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

HIP1 is an inclusion eligibility criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain HIP1 status and therapy-related acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is altered in 7.23% of therapy-related acute myeloid leukemia patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH2 is altered in 6.02% of therapy-related acute myeloid leukemia patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

IL7R is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains IL7R status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

JAK1 is altered in 3.85% of therapy-related acute myeloid leukemia patients [2].

JAK1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

JAK2 is altered in 4.82% of therapy-related acute myeloid leukemia patients [2].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

JAK3 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains JAK3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2A is altered in 1.56% of therapy-related acute myeloid leukemia patients [2].

KMT2A is an inclusion eligibility criterion in 6 clinical trials for therapy-related acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain KMT2A status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 5 are phase 2 (5 open) [3].

KRAS is altered in 2.41% of therapy-related acute myeloid leukemia patients [2].

KRAS is an inclusion eligibility criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

LYN is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains LYN status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 8 clinical trials for therapy-related acute myeloid leukemia, of which 8 are open and 0 are closed. Of the trials that contain MECOM status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 7 are phase 2 (7 open) [3].

MLF1 is an inclusion eligibility criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain MLF1 status and therapy-related acute myeloid leukemia as inclusion criteria, 3 are phase 2 (3 open) [3].

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MLLT10 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT3 is altered in 3.85% of therapy-related acute myeloid leukemia patients [2].

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MLLT3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MLLT4 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NF1 is altered in 7.69% of therapy-related acute myeloid leukemia patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

NPM1 is altered in 4.82% of therapy-related acute myeloid leukemia patients [2].

NPM1 is an inclusion eligibility criterion in 4 clinical trials for therapy-related acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain NPM1 status and therapy-related acute myeloid leukemia as inclusion criteria, 4 are phase 2 (4 open) [3].

NRAS is altered in 9.64% of therapy-related acute myeloid leukemia patients [2].

NRAS is an inclusion eligibility criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain NRAS status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NRIP3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain NUP214 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain PDGFRB status and therapy-related acute myeloid leukemia as inclusion criteria, 3 are phase 2 (3 open) [3].

PRDM16 is an inclusion eligibility criterion in 2 clinical trials for therapy-related acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain PRDM16 status and therapy-related acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].

PTPN11 is altered in 7.23% of therapy-related acute myeloid leukemia patients [2].

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTPN11 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

RIT1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 8 clinical trials for therapy-related acute myeloid leukemia, of which 8 are open and 0 are closed. Of the trials that contain RPN1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 7 are phase 2 (7 open) [3].

RUNX1 is altered in 7.23% of therapy-related acute myeloid leukemia patients [2].

RUNX1 is an inclusion eligibility criterion in 5 clinical trials for therapy-related acute myeloid leukemia, of which 5 are open and 0 are closed. Of the trials that contain RUNX1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [3].

SF3B1 is altered in 2.41% of therapy-related acute myeloid leukemia patients [2].

SF3B1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

SH2B3 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SH2B3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

SRSF2 is altered in 10.84% of therapy-related acute myeloid leukemia patients [2].

SRSF2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

STAG2 is altered in 9.38% of therapy-related acute myeloid leukemia patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is altered in 36.14% of therapy-related acute myeloid leukemia patients [2].

TP53 is an inclusion eligibility criterion in 3 clinical trials for therapy-related acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain TP53 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

TYK2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TYK2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

U2AF1 is altered in 2.41% of therapy-related acute myeloid leukemia patients [2].

U2AF1 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains U2AF1 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

ZRSR2 is altered in 1.2% of therapy-related acute myeloid leukemia patients [2].

ZRSR2 is an inclusion eligibility criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ZRSR2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].